5,7-Dimethylpyrrolo<2,3-b>pyrazin | 20322-06-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡嗪类
• 英文名称: 5,7-Dimethylpyrrolo<2,3-b>pyrazin
• 英文别名: 5,7-dimethyl-5H-pyrrolo[2,3-b]pyrazine；5,7-Dimethylpyrrolo[2,3-b]pyrazine
• CAS: 20322-06-9
• 化学式: C₈H₉N₃
• 分子量: 147.18
• InChiKey: KWPOIJVDQOYPKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Novel Heteroaryl Derivative
  申请人：Takahashi Yoko

  公开号：US20080167306A1

  公开（公告）日：2008-07-10

  A compound of the following formula (1), or its prodrug or pharmaceutically acceptable salt thereof, being useful as a diabetic medicine or preventive, or blood sugar regulator, or therapeutic agent for hyperlipemia, etc. wherein the ring Z is an optionally substituted heteroaryl, W 4 is a single bond, lower alkylene, etc., Ar 2 is an optionally substituted aryl, etc., W 3 is a single bond, lower alkylene, etc., Ar 1 is an optionally substituted arylene, etc., each of W 1 and W 2 is an optionally substituted lower alkylene, etc., and R 1 is carboxyl, an alkoxycarbonyl.

  下列式子（1）的化合物，或其前药或其药学上可接受的盐，被用作糖尿病药物或预防药物，或血糖调节剂，或高脂血症等治疗剂。其中，环Z是可选取代的杂芳基，W4是单键，低碳链等，Ar2是可选取代的芳基等，W3是单键，低碳链等，Ar1是可选取代的芳烃基等，W1和W2是可选取代的低碳链等，R1是羧基，烷氧羰基等。
• HETEROARYL DERIVATIVES
  申请人：TAKAHASHI Yoko

  公开号：US20100286144A1

  公开（公告）日：2010-11-11

  A compound of the following formula (1), or its prodrug or pharmaceutically acceptable salt thereof, being useful as a diabetic medicine or preventive, or blood sugar regulator, or therapeutic agent for hyperlipemia, etc. wherein the ring Z is an optionally substituted heteroaryl, W 4 is a single bond, lower alkylene, etc., Ar 2 is an optionally substituted aryl, etc., W 3 is a single bond, lower alkylene, etc., Ar 1 is an optionally substituted arylene, etc., each of W 1 and W 2 is an optionally substituted lower alkylene, etc., and R 1 is carboxyl, an alkoxycarbonyl.

  以下式子（1）的化合物，或其前药或药学上可接受的盐，可用作糖尿病药物、预防药物、血糖调节剂或高脂血症等治疗剂。 其中，环Z是可选取的取代杂环基，W4是单键，低碳烷基等，Ar2是可选取的取代芳基等，W3是单键，低碳烷基等，Ar1是可选取的取代芳烃基等，W1和W2各自是可选取的取代低碳烷基等，R1是羧基，烷氧羰基等。
• NOVEL HETEROARYL DERIVATIVE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1837329A1

  公开（公告）日：2007-09-26

  A compound of the following formula (1), or its prodrug or pharmaceutically acceptable salt thereof, being useful as a diabetic medicine or preventive, or blood sugar regulator, or therapeutic agent for hyperlipemia, etc. wherein the ring Z is an optionally substituted heteroaryl, W4 is a single bond, lower alkylene, etc., Ar2 is an optionally substituted aryl, etc., W3 is a single bond, lower alkylene, etc., Ar1 is an optionally substituted arylene, etc., each of W1 and W2 is an optionally substituted lower alkylene, etc., and R1 is carboxyl, an alkoxycarbonyl.

  下式(1)化合物或其原药或药学上可接受的盐，可用作糖尿病药物或预防药物，或血糖调节剂，或高脂血症治疗剂等。 其中，环 Z 是任选取代的杂芳基，W4 是单键、低级亚烷基等，Ar2 是任选取代的芳基等，W3 是单键、低级亚烷基等，Ar1 是任选取代的芳基等，W1 和 W2 各自是任选取代的低级亚烷基等，R1 是羧基、烷氧羰基。
• US7781479B2
  申请人：——

  公开号：US7781479B2

  公开（公告）日：2010-08-24
• [EN] MONOACYLGLYCEROL LIPASE MODULATORS<br/>[FR] MODULATEURS DE LA MONOACYLGLYCÉROL LIPASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020065614A1

  公开（公告）日：2020-04-02

  Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. and; wherein R2, R3 R4, R5 and R6 are defined herein.